Beta Bionics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Beta Bionics, Inc.
Medtech Insight's News We're Watching highlights medtech industry developments that you may have missed over the last few weeks. In addition to the big news from Acutus, Apple, and Illumina, Masimo scored an important FDA clearance, Beta Bionics announced the US launch of its iLet bionic pancreas for Dexcom’s G7 CGM, and more.
After receiving US FDA clearance in May, Beta Bionics secured $100m in financing which is expected to be used to commercialize its iLet Bionic Pancreas and “further develop and test the bi-hormonal bionic pancreas.”
The global insulin pump market is expected to see double-digit growth, reaching $5.1bn in 2024, with product launches expected by Medtronic, Insulet, Tandem and smaller players in 2021.
Tandem Diabetes Care received FDA clearance for its Control-IQ technology for use with Tandem's t:slim X2 insulin pump and Dexcom's G6 continuous glucose monitoring system, making it the first hybrid closed-loop system to deliver automatic correction boluses and adjust background insulin levels to help prevent high and low blood sugars.
- Medical Devices
- Drug Delivery
- Monitoring Equipment & Devices
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.